Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
Section 16. Form 4 or Form 5		
obligations may continue. See		

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Iversen Leslie L</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				ner	
(Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC. 3911 SORRENTO VALLEY BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 06/11/2010  4. If Amendment, Date of Original Filed (Month/Day/Year)									below			Other (s below)		
(Street) SAN DII			92121 (Zip)		4. IT AI	mena	iment, L	oate (	or Onginai Fili	ea (M	viontn/Da	y/ Year)	Lin	X Form	iled by One	e Repo	orting Person	n
		Tab	le I - Non-	Deriva	tive S	Secu	urities	Ac	quired, Di	ispo	osed o	f, or Bei	neficial	ly Owned	l			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 ar		Benefici Owned I	s ally ollowing	Form	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
			Code V			7	Amount	(A) or (D)		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ransaction of E code (Instr. Derivative (		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4)			es g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Co	de V	(	(A)	(D)	Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares					
Stock option (right to buy)	\$1.3	06/11/2010		A	A	1	10,000		(1)	06/3	10/2020	Common stock	10,000	\$0	10,00	0	D	
Stock option (right to	\$1.3	06/11/2010		A	A	7	75,000		(1)	06/:	10/2020	Common stock	75,000	(2)	75,00	0	D	

## **Explanation of Responses:**

- 1. 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.
- 2. The Reporting Person has elected to convert annual retainer fees of \$32,500 into a stock option under the terms of the Issuer's Outside Director Compensation Program.

/s/ Thomas H. Aasen, Attorney-06/15/2010 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.